Moreover, expression of IGF1R and SphK1/SIP-receptors has been shown to contribute to tamoxifen resistance in ER-positive breast cancer [16, 25, 26] which further highlights the need to better understand the significance of IGF1R and SphK1 co-expression and their contribution to anti-estrogen therapy resistance in breast cancer. Here, IGF1R is linked to breast cancer.